There are 2867 resources available
107P - Systematic characterization of MET activating mutations in non-small cell lung cancer
Presenter: Yao Yu
Session: Poster session 01
108P - Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition
Presenter: Andrew Davis
Session: Poster session 01
109P - Improved accuracy of somatic variant detection from high throughput sequencing (HTS) data via site-specific noise estimation
Presenter: Ekaterina Ignatova
Session: Poster session 01
110P - Characteristics and survival outcomes of patients (pts) with RET fusion-positive (RET-fp) solid tumours receiving non-RET inhibitor (RETi) therapy in a real-world setting
Presenter: Pilar Garrido Lopez
Session: Poster session 01
111P - Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
Presenter: Ghanashyam Sarikonda
Session: Poster session 01
112P - Beyond BRAF V600: Characterizing the genomic landscape of non-BRAF V600 mutations and BRAF fusions in 121,221 in adult patients with cancer
Presenter: Niamh Coleman
Session: Poster session 01
113P - Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial
Presenter: Michele Maio
Session: Poster session 01
115P - Combination of two distinct subsets of peripheral blood CD8+ T cells from patients with NSCLC predicts response outcome to immune checkpoint inhibitor therapy
Presenter: Jae-Ho Cho
Session: Poster session 01
116P - Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis
Presenter: Talal El Zarif
Session: Poster session 01